Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Bortezomib [179324-69-7]

Bortezomib [179324-69-7]

Imprimer Imprimer
Identifiez-vous

Référence 10-2120-5mg

Conditionnement : 5mg

Marque : Focus Biomolecules

Demander plus d'informations

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Bortezomib | Proteasome inhibitor

CAS:
179324-69-7
Catalog Number:
10-2120
Activity:
Proteasome inhibitor
Alternate Names:
MG-341, PS-341
Chemical Name:
N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Molecular Weight:
384.25
Molecular Formula:
C19H25BN4O4
Solubility:
Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 35 mg/ml).
Physical Properties:
White solid
Purity:
98% by TLC
NMR (conforms)
Storage Temperature:
-20°
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Shipping Code:
RT

Available Options

size : Quantity 
5 mg$60.00
25 mg$200.00
Request Quote / Bulk / Custom Size
Product Inquiry

Bortezomib (179324-69-7) is a potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM).  Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma.3 Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved.4 Reversible. Cell permeable.

References/Citations:

1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615
2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835
3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361
4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

CAS:
179324-69-7
Catalog Number:
10-2120
Activity:
Proteasome inhibitor
Alternate Names:
MG-341, PS-341
Chemical Name:
N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Molecular Weight:
384.25
Molecular Formula:
C19H25BN4O4
Solubility:
Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 35 mg/ml).
Physical Properties:
White solid
Purity:
98% by TLC
NMR (conforms)
Storage Temperature:
-20°
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee

Bortezomib (179324-69-7) is a potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM).  Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma.3 Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved.4 Reversible. Cell permeable.

References/Citations:

1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615
2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835
3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361
4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
A11260-10
MLN4924 [905579-51-3]
 10mg 
10-1309-5mg
MG-132 [133407-82-6]
 5mg 
10-2126-5mg
Dasatinib [302962-49-8]
 5mg